Venous Thromboembolism News and Research

RSS

Blood type, blood protein mutations influence thromboembolism risk

Findings from two Danish studies have shown that ABO blood type, both alone and in combination with the presence of factor V and prothrombin mutations, is associated with increases in risk for venous thromboembolism.

20 Feb 2013

Rivaroxaban ruled out for extended thromboprophylaxis

The benefits of extended prophylactic anticoagulation with rivaroxaban in acutely ill hospital patients are outweighed by an increased bleeding risk, shows a study in The New England Journal of Medicine.

14 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Non-O blood type - the most important risk factor for venous thromboembolism

The non-O ABO blood type is the most important risk factor for venous thromboembolism (blood clots in veins), making up 20% of attributable risk for the condition, according to a new study in CMAJ (Canadian Medical Association Journal).

6 Feb 2013

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013

Selective strategy for D-dimer testing in DVT

Selecting certain patients for D-dimer testing appears to be a safe and more efficient way of diagnosing deep vein thrombosis than uniformly testing all patients suspected of having the condition, report researchers.

16 Jan 2013

Link between infections and venous thromboembolism in surgical patients

Despite receiving blood thinners and other clot prevention treatment, some patients still develop potentially lethal blood clots in the first month after their operations anyway, especially if they developed a surgical-site infection while in the hospital, according to results of a study at Johns Hopkins.

16 Jan 2013

Studies examine current treatment standards for patients with clotting disorders

Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes.

11 Dec 2012

Combined oral contraceptives increase risk of blood clots in women with PCOS

Women with polycystic ovary syndrome (PCOS) who are taking combined oral contraceptives have a 2-fold risk of blood clots compared with women without the disorder who take contraceptives, states a study published in CMAJ (Canadian Medical Association Journal).

4 Dec 2012

Low-dose aspirin effective at preventing serious blood clots

Low-dose aspirin is a cheap and effective way to prevent potentially deadly blood clots in the leg or the lungs in patients who have had a previous blood clot a new study shows.

6 Nov 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).

3 Nov 2012

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients.

2 Nov 2012

Isis commences ISIS-FXIRx Phase 2 study in knee replacement surgery patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA).

29 Oct 2012

VTE care improvements may be linked to implementation of treatment guidelines

The quality of care of patients hospitalized with venous thromboembolism (VTE) significantly improved between 2005 and 2009, and researchers suggest these improvements may be due to the implementation of VTE treatment guidelines.

22 Oct 2012

Obesity does not affect VTE risk after knee surgery

Being morbidly obese does not increase the risk for developing venous thromboembolism after total knee arthroplasty surgery, report US researchers.

15 Oct 2012

Best-practices protocol significantly reduces ventilator-associated pneumonia

An intensive care unit-initiated protocol implementing “best practices” significantly reduces ventilator-associated pneumonia, research shows.

8 Oct 2012

VTE risk highlighted for rheumatoid arthritis patients

Individuals with rheumatoid arthritis are at an increased risk for venous thromboembolism, research confirms.

8 Oct 2012

Patients with RA more likely to develop venous thromboembolism

A study that included more than 45,000 residents of Sweden with rheumatoid arthritis finds that individuals with this disease had an associated higher risk of venous thromboembolism (a blood clot that forms within a vein), and that this elevated risk was stable for 10 years after the time of diagnosis, according to a study in the October 3 issue of JAMA.

3 Oct 2012

Many AF patients not receiving oral anticoagulant therapy despite rapid adoption of dabigatran

A novel blood thinner recently approved by the FDA, dabigatran (Pradaxa), has been rapidly adopted into clinical practice, yet thus far has had little impact on improving treatment rates for atrial fibrillation.

24 Sep 2012